Edition:
United States

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.64USD
8 Dec 2017
Change (% chg)

$0.14 (+4.00%)
Prev Close
$3.50
Open
$3.49
Day's High
$3.66
Day's Low
$3.48
Volume
19,065
Avg. Vol
23,807
52-wk High
$12.09
52-wk Low
$3.26

Chart for

About

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The... (more)

Overall

Beta: 0.31
Market Cap(Mil.): $67.89
Shares Outstanding(Mil.): 18.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

Dec 08 2017

BRIEF-Novelion Therapeutics Appoints Michael Price As CFO

* NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

Dec 04 2017

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

* Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice

Nov 21 2017

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

Nov 20 2017

UPDATE 1-U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

Nov 20 2017

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was "not in the public interest."

Nov 20 2017

BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results

* Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change

Nov 09 2017

U.S. submits revised plea deal with Novelion's Aegerion to court

BOSTON The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement.

Nov 01 2017

U.S. submits revised plea deal with Novelion's Aegerion to court

BOSTON, Nov 1 The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement.

Nov 01 2017

U.S. judge says he may reject plea deal with Novelion's Aegerion

BOSTON A U.S. judge on Wednesday said he may reject a plea agreement that was part of Aegerion Pharmaceuticals Inc's recent $36 million settlement with the U.S. Justice Department, saying he was not happy with its sentencing terms.

Oct 18 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,135 -26.00
Pfizer Inc. (PFE.N) $35.74 +0.24
Novartis AG (NOVN.S) CHF83.10 +1.05
Merck & Co., Inc. (MRK.N) $55.57 +0.80
Roche Holding Ltd. (ROG.S) CHF240.50 -1.80
Roche Holding Ltd. (RO.S) CHF242.50 -1.40
Bayer AG (BAYGn.DE) €104.70 +0.55
Bayer AG (BAYE.F) -- --
AstraZeneca plc (AZN.L) 4,784.00 +79.00
Allergan, Inc. (AGN.N) $167.80 +2.93

Earnings vs. Estimates